- Home
- SEMR vs ELVN Comparison
SEMR vs ELVN Comparison
Compare SEMR & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- ELVN
- Stock Information
- Founded
- SEMR 2008
- ELVN 2016
- Country
- SEMR United States
- ELVN United States
- Employees
- SEMR N/A
- ELVN N/A
- Industry
- SEMR EDP Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- ELVN Health Care
- Exchange
- SEMR Nasdaq
- ELVN Nasdaq
- Market Cap
- SEMR 1.1B
- ELVN 1.2B
- IPO Year
- SEMR 2021
- ELVN 2020
- Fundamental
- Price
- SEMR $7.35
- ELVN $21.72
- Analyst Decision
- SEMR Buy
- ELVN Strong Buy
- Analyst Count
- SEMR 6
- ELVN 5
- Target Price
- SEMR $13.50
- ELVN $41.20
- AVG Volume (30 Days)
- SEMR 1.2M
- ELVN 556.8K
- Earning Date
- SEMR 11-05-2025
- ELVN 11-12-2025
- Dividend Yield
- SEMR N/A
- ELVN N/A
- EPS Growth
- SEMR N/A
- ELVN N/A
- EPS
- SEMR N/A
- ELVN N/A
- Revenue
- SEMR $413,962,000.00
- ELVN N/A
- Revenue This Year
- SEMR $20.28
- ELVN N/A
- Revenue Next Year
- SEMR $16.41
- ELVN $20.05
- P/E Ratio
- SEMR N/A
- ELVN N/A
- Revenue Growth
- SEMR 22.16
- ELVN N/A
- 52 Week Low
- SEMR $6.91
- ELVN $13.30
- 52 Week High
- SEMR $18.74
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- SEMR 48.88
- ELVN 59.46
- Support Level
- SEMR $6.91
- ELVN $19.98
- Resistance Level
- SEMR $7.45
- ELVN $21.81
- Average True Range (ATR)
- SEMR 0.31
- ELVN 0.93
- MACD
- SEMR 0.02
- ELVN 0.18
- Stochastic Oscillator
- SEMR 55.00
- ELVN 79.43
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.